Skip to main content
. 2021 Nov;10(11):4161–4173. doi: 10.21037/tlcr-21-536

Figure 1.

Figure 1

The clinical course. All three cases were histologically identified as transformed after EGFR-TKI treatment. HE, hematoxylin-eosin; DEL, deletion mutation in exon 19; EGFR, epidermal growth factor receptor; CBDCA, carboplatin; GEM, gemcitabine; PEM, pemetrexed; Bev, bevacizumab; PTX, paclitaxel; TBLB, transbronchial lung biopsy, DOC, docetaxel; Nivo, nivolumab.